Arcutis Biotherapeutics, Inc. (ARQT) vs Denali Therapeutics Inc. (DNLI)
Arcutis Biotherapeutics, Inc. and Denali Therapeutics Inc. are both Biotechnology companies. Arcutis Biotherapeutics, Inc. and Denali Therapeutics Inc. are of similar size ($3.4B and $3.4B). Denali Therapeutics Inc. has negative trailing earnings, so its P/E is not meaningful; Arcutis Biotherapeutics, Inc. trades at 122×. Denali Therapeutics Inc. grew revenue faster over the last twelve months: 194.7% against 76.1%. Arcutis Biotherapeutics, Inc. has the higher net margin (6.15% vs −171.1%) and the higher return on invested capital (23.6% vs −260.5%). Across the 17 metrics below, Arcutis Biotherapeutics, Inc. leads on 11 and Denali Therapeutics Inc. on 6.
Valuation
Profitability
| Metric | ARQT | DNLI | Biotechnology median |
|---|---|---|---|
| Gross margin | 91.14% | 99.97% | 65.16% |
| Operating margin | 7.38% | (181.51%) | 0.00% |
| Net margin | 6.15% | (171.06%) | 0.00% |
| Free cash flow margin | 8.42% | (146.31%) | 0.00% |
| Return on equity | 15.86% | (54.93%) | (57.72%) |
| Return on assets | 6.78% | (44.01%) | (49.22%) |
| Return on invested capital | 23.62% | (260.54%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack